# A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

> **NCT04426357** · PHASE1 · TERMINATED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 6 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** JNJ-64417184

## Key facts

- **NCT ID:** NCT04426357
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-03
- **Primary completion:** 2020-11-12
- **Final completion:** 2020-11-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** company decision
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04426357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04426357, "A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04426357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*